India Pharma Outlook Team | Wednesday, 04 November 2026
Sterile drug manufacturing in India could face tighter microbial contamination controls as the Union Health Ministry proposes amendments to Schedule M of the Drugs Rules, 1945, aligning requirements with WHO guidelines.
Published through a draft notification, the proposal seeks to revise microbial contamination limits for sterile pharmaceutical production environments.
It introduces a no-growth requirement for Grade A areas, where critical aseptic operations take place.
The proposed changes could push manufacturers to strengthen environmental monitoring, contamination-control systems and quality assurance practices as India seeks closer alignment with international manufacturing standards.
The proposed amendment seeks to replace Table 3 under Requirement 4, paragraph 4.9, Part II of Schedule M, which covers sterile products, parenteral preparations and sterile ophthalmic preparations.
The revised microbial contamination limits are as follows:
For contact plates, the proposed limits are 5 CFU for Grade B, 25 CFU for Grade C and 50 CFU for Grade D. Grade B also carries a glove-print limit of 5 CFU per glove. No growth is specified for Grade A.
The proposal also aligns with WHO Technical Report Series 1044, Annex 2, concerning good manufacturing practices for sterile pharmaceutical products.
Also Read: Strengthening India's Pharma Quality Infrastructure
Grade A areas are critical environments in which exposed products, containers and sterilized components are handled. These zones are particularly important during aseptic filling and connections because microbial contamination can compromise the sterility of finished medicines.
For sterile drug manufacturing facilities, maintaining these environments requires controlled airflow, appropriate filtration, personnel hygiene, equipment sanitation and continuous environmental monitoring.
The proposed microbial contamination limits therefore place greater importance on the effectiveness of cleanroom monitoring and contamination-control strategies.
Manufacturers may need to examine their sampling procedures, microbiological testing capabilities and investigation protocols to ensure that contamination events are identified and addressed promptly.
Companies operating sterile production facilities may need to evaluate whether their existing environmental monitoring programs, microbiology laboratories and aseptic processing controls are adequate to meet the proposed requirements.
For Indian pharmaceutical manufacturers supplying international markets, WHO GMP compliance also carries wider significance. Alignment with internationally recognized manufacturing practices can support confidence in the domestic production system.
The government has invited objections and suggestions from affected stakeholders, with the draft rules to be considered after the prescribed 30-day consultation period following publication in the Gazette.
Pharmaceutical manufacturers, industry associations and quality-control professionals therefore have an opportunity to assess the proposed requirements and communicate implementation concerns.
For India's sterile drug manufacturing industry, the development signals a stronger regulatory focus on microbial contamination prevention, environmental monitoring and consistency in aseptic production.
.jpg)
